Chronic Heart Failure Circulatory System Chronic Heart Failure
Conditions
Interventions
Allopurinol 300 mg versus allopurinol 600 mg versus placebo
Sponsors
University of Dundee (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Three-month period free of hospitalisations prior to screening 2. Ability to give written informed consent to participate in the study 3. Diagnosis of mild to moderate chronic heart failure
Exclusion criteria
Exclusion criteria: 1. History of drug sensitivity or allergy to allopurinol or vitamin C 2. Current treatment with allopurinol , theophylline or cytotoxic drugs (including azothiaprine or mercaptopurine) 3. History of acute gout 4. Evidence of significant disease that could impair absorption, metabolism or excretion of orally administered medication i.e. a. Renal disease (serum creatinine >160 umol/l) b. Clinically significant hepatic disease (either by lab work, i.e. alanine aminotranferease (ALT) and aspartate aminotransferase (AST) (ALT/AST > 3 times upper limit of normal, or by clinical assessment) 5. Any condition with sufficient severity to impair co-operation in the study 6. History of chronic alcoholism / intravenous drug abuse 7. Use of another investigational drug within three months of entry into the study or within five half-lives of the investigational drug (the longer time period applying) 8. Pregnancy, breast feeding or being of childbearing age and not taking oral contraceptives
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in endothelial function | — |
Secondary
| Measure | Time frame |
|---|---|
| Urate levels and oxidative stress burden | — |
Countries
United Kingdom
Outcome results
None listed